Rigel Pharmaceuticals
RIGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$899.06M
Close$
$-29.43
161.1% downside
Current Fair Value
161.1% downsideOvervalued by 161.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $899.06 Million |
|---|---|
| Enterprise Value | $906.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $20.4 |
| Beta | 1.19 |
| Outstanding Shares | 18,541,000 |
Return
| Return on Equity | 75.67% |
|---|---|
| Return on Assets | 61.78% |
| Return on Invested Capital | 20.18% |
Valuation & Multiples
| P/E Ratio | 2.72 |
|---|---|
| PEG | -3.84 |
| Price to Sales | 3.44 |
| Price to Book Ratio | 2.19 |
| Enterprise Value to Revenue | 3.27 |
| Enterprise Value to EBIT | 10.55 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$55.27 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.92
Average shareholder expectationRevenue Estimate
$80.10 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 58.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.16%▼ 85.67% |
|---|---|
| Total Invested | $37.12M▼ 94.26% |
| Investors Holding | 24▼ 137.00% |
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez